SEC Filing Analysis: QUEST DIAGNOSTICS INC (DGX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Quest Diagnostics strengthens its board with the appointment of Timothy Wentworth, former CEO of Walgreens Boots Alliance.
• Market Impact: Neutral financially; positive qualitative signal for corporate governance.

Company Information

Field	Value
Company	QUEST DIAGNOSTICS INC
Ticker Symbol	DGX
CIK	0001022079
Industry	Services-Medical Laboratories

Insider Information

Field	Value
Name	Timothy Wentworth
CIK	null
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	8-K
Transaction Date	2026-03-09
Transaction Code	A (Grant)
Security Type	Restricted Share Units
Shares Involved	null (Value specified only)
Price Per Share	null
Total Value	~$43,000
Shares Owned After	null
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	~$43,000
% of Market Cap	~0.0002%
Shares Transacted	null
% of Shares Outstanding	Negligible
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of $21.89 billion, a $43,000 grant is financially immaterial.
• Ownership Concentration: This is an initial grant for a new director; ownership concentration impact is nil.
• Dilution Impact: The grant represents a microscopic fraction of the 109.87 million shares outstanding.
• Transaction Significance: The significance lies in the person (former Walgreens CEO) rather than the amount.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While the addition of a high-profile director is a positive governance indicator, the financial transaction itself is a standard compensatory grant that will not drive price action.

Volume & Sentiment

• Expected Volume Impact: None.
• Sentiment Indicator: Neutral to Slightly Bullish (Long-term governance view).

Additional Context

Transaction Notes

• Timing: Appointment effective March 9, 2026.
• Special Circumstances: Mr. Wentworth serves on the Compensation and Leadership Development Committee and the Quality and Compliance Committee. The grant is a prorated one-time award upon joining the board.